CA2093132C - Process for the preparation of imidazo[4,5-c]quinolin-4-amines - Google Patents
Process for the preparation of imidazo[4,5-c]quinolin-4-amines Download PDFInfo
- Publication number
- CA2093132C CA2093132C CA002093132A CA2093132A CA2093132C CA 2093132 C CA2093132 C CA 2093132C CA 002093132 A CA002093132 A CA 002093132A CA 2093132 A CA2093132 A CA 2093132A CA 2093132 C CA2093132 C CA 2093132C
- Authority
- CA
- Canada
- Prior art keywords
- carbon atoms
- formula
- compound
- group
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
A process is disclosed for preparing 1-substituted-1H-imidazo[4,5-c]quinolin-4-amines of formula (I). The process involves reacting a 1-substituted-1H-imidazo[4,5-c]quinoline-5-oxide with an acylating agent and reacting the product thereof with an ami-nating agent.
Description
~O 92/06093 -1- ~ ~ 9 3 ~ 3 2 PCT/US91/06682 PROCESS FOR THE PREPARATION
OF IMIDAZO [4,5-C] QUINOhIN-4-AMINES
BACKGROUND OF THE INVENTION
Field of the Invent' on This invention relates to processes for preparing 1H-imidazo[4,5-c)quinolines. In another aspect this invention relates to processes for preparing 1-substituted-1H-i.m:idazo[4,5-c]quinolin-4-amines.
Description of th e~~elated Art The synthesis of 1H-imidazo[4,5-c]quinolin-4-amines has been described in U.S. Pat. Nos. 4,689,338 (Gerster) and 4,929,624 (Gerster et al.). The methods described therein involve the step of heating the 4-chloro compound in the presence of ammonium hydroxide or ammonia under pressure (e.g., in a sealed reactor) to afford the 4-amino compound.
Khim. Geterosiklicheskikh Soedinenii 1976, 2, 229 (Solekhova et a:l.) describes the amination of pyridine N-oxide and quinoline N-oxide at the 2-position with ammonia and some ammonia salts in the presence of p-toluenesulfonyl chloride: Similarly, Chem. Pharm. Bull.
(Tokyo) 1984, 1, 35 (Hamana et al.) describes the reaction between quinoline 1~-oxide and various amines in the presence of an acylating agent.
SUMMARY OF THE INVENTION
This invention provides a process for preparing a compound of Formula I
OF IMIDAZO [4,5-C] QUINOhIN-4-AMINES
BACKGROUND OF THE INVENTION
Field of the Invent' on This invention relates to processes for preparing 1H-imidazo[4,5-c)quinolines. In another aspect this invention relates to processes for preparing 1-substituted-1H-i.m:idazo[4,5-c]quinolin-4-amines.
Description of th e~~elated Art The synthesis of 1H-imidazo[4,5-c]quinolin-4-amines has been described in U.S. Pat. Nos. 4,689,338 (Gerster) and 4,929,624 (Gerster et al.). The methods described therein involve the step of heating the 4-chloro compound in the presence of ammonium hydroxide or ammonia under pressure (e.g., in a sealed reactor) to afford the 4-amino compound.
Khim. Geterosiklicheskikh Soedinenii 1976, 2, 229 (Solekhova et a:l.) describes the amination of pyridine N-oxide and quinoline N-oxide at the 2-position with ammonia and some ammonia salts in the presence of p-toluenesulfonyl chloride: Similarly, Chem. Pharm. Bull.
(Tokyo) 1984, 1, 35 (Hamana et al.) describes the reaction between quinoline 1~-oxide and various amines in the presence of an acylating agent.
SUMMARY OF THE INVENTION
This invention provides a process for preparing a compound of Formula I
N, \\~R2 - N
i CR)n wherein:
R1 is straight chain or branched chain alkyl of 1 to 10 carbon atoms; straight chain or branched chain alkenyl of 3 to 10 carbon atoms wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the 1-nitrogen; substituted straight chain or branched chain alkenyl of 3 to 10 carbon atoms wherein the olefinic unsaturation is at least one carbon atom removed from the 1-nitrogen, wherein the substituent is selected from the group consisting of lower alkyl, cycloalkyl of 3 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms substituted by lower alkyl; and substituted straight chain or branched chain alkyl of 1 to 10 carbon atoms, wherein the substituent is selected from the group consisting of lower alkyl, cycloalkyl of 3 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms substituted by lower alkyl;
R2 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing 1 to 8 carbon atoms ; benzyl , (phenyl ) ethyl and phenyl , the benzyl, (phenyl)ethyi or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso 2a that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than 6 carbon atoms;
each R is independently selected from the group consisting of lower alkoxy, halogen, and lower alkyl, and n is an integer from 0 to 2, with the proviso that if n is ~O 92/06093 2, then said R groups together contain no more than 6 carbon atoms; or a pharmaceutically acceptable acid addition salt thereof, which process comprises the steps of (i) providing a compound of Formula II
-o N
N o ~-'N
I
CR)n II
wherein R, n, R1, and RZ are as defined above;
(ii) reacting the compound of Formula II
with an acylating agent; and (iii) reacting the product of step (ii) with an aminating agent in an inert solvent to provide a compound of Formula I; and (iv) isolating the compound of Formula I
or a pharmaceutically acceptable acid addition salt thereof .
This invention provides a process by which an N-oxide of Formula II can be aminated without the use of the high pressure conditions used in previous syntheses of imida~zo[4,5-c]quinolin-4-amines, and without isolation of an intermediate. The process of this invention is therefore more convenient than the previous syntheses.. Moreover, yield and purity of the product of Formula. I is improved by the process of this invention.
DETAILED DESCRIPTION OF THE INVENTION
For the purpose of the instant specification and claims, the team "lower" when used in connection with "alkyl" or "a.lkoxy" designates straight chain or branched chain groups containing 1 to about 4 carbon atoms.
WO 92/06093 PCT/US91/06~~?
i CR)n wherein:
R1 is straight chain or branched chain alkyl of 1 to 10 carbon atoms; straight chain or branched chain alkenyl of 3 to 10 carbon atoms wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the 1-nitrogen; substituted straight chain or branched chain alkenyl of 3 to 10 carbon atoms wherein the olefinic unsaturation is at least one carbon atom removed from the 1-nitrogen, wherein the substituent is selected from the group consisting of lower alkyl, cycloalkyl of 3 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms substituted by lower alkyl; and substituted straight chain or branched chain alkyl of 1 to 10 carbon atoms, wherein the substituent is selected from the group consisting of lower alkyl, cycloalkyl of 3 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms substituted by lower alkyl;
R2 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing 1 to 8 carbon atoms ; benzyl , (phenyl ) ethyl and phenyl , the benzyl, (phenyl)ethyi or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso 2a that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than 6 carbon atoms;
each R is independently selected from the group consisting of lower alkoxy, halogen, and lower alkyl, and n is an integer from 0 to 2, with the proviso that if n is ~O 92/06093 2, then said R groups together contain no more than 6 carbon atoms; or a pharmaceutically acceptable acid addition salt thereof, which process comprises the steps of (i) providing a compound of Formula II
-o N
N o ~-'N
I
CR)n II
wherein R, n, R1, and RZ are as defined above;
(ii) reacting the compound of Formula II
with an acylating agent; and (iii) reacting the product of step (ii) with an aminating agent in an inert solvent to provide a compound of Formula I; and (iv) isolating the compound of Formula I
or a pharmaceutically acceptable acid addition salt thereof .
This invention provides a process by which an N-oxide of Formula II can be aminated without the use of the high pressure conditions used in previous syntheses of imida~zo[4,5-c]quinolin-4-amines, and without isolation of an intermediate. The process of this invention is therefore more convenient than the previous syntheses.. Moreover, yield and purity of the product of Formula. I is improved by the process of this invention.
DETAILED DESCRIPTION OF THE INVENTION
For the purpose of the instant specification and claims, the team "lower" when used in connection with "alkyl" or "a.lkoxy" designates straight chain or branched chain groups containing 1 to about 4 carbon atoms.
WO 92/06093 PCT/US91/06~~?
The process of this invention is illustrated in the Reaction Scheme below, wherein R, n, R" and Rz are as defined above.
Reaction Scheme I I
~1~ A~ NCO- (~ A gv OH ~$ ~Ci (R)n CE)n (R)n III IV
V
(3) O
O
~8z r ( 4 ) Hs _ N A~ O
I
R1 \HH
I
(8)n II Ri (R)n vI
Reaction Scheme I I
~1~ A~ NCO- (~ A gv OH ~$ ~Ci (R)n CE)n (R)n III IV
V
(3) O
O
~8z r ( 4 ) Hs _ N A~ O
I
R1 \HH
I
(8)n II Ri (R)n vI
(5) A$2 1!~ A~g2 (~l _ /g I
$i (R)n The Reaction Scheme begins with a 4-hydroxyquinoline of Formula III. Many 4-hydroxyquinolines of Formula III are commercially available. The others are known and/or can be prepared readily by those skilled in the art. Step 1 involves nitration of a 4-hydroxyquinoline to provide a 3-nitro-4-hydroxyquinoline of Formula IV. Conventional conditions for such reactions are well known.
Preferred conditions in the instance where n is zero, which afford a product of Formula IV in superior yield compared with conolitions used in the prior art, involve heating at: about 125°C-130°C in propionic acid in the presence of nitric acid. Preferred conditions in other instances. will depend upon the particular 4-hydroxyquinoline: used in step 1, and those skilled in the art will be: able to select suitable conditions.
In step 2, a 3-vitro-4-hydroxyquinoline is chlorinated at the: 4-position to provide a 3-vitro-4-chloroquinoline of Formula V. Some compounds of Formula V are knowm and disclosed, e.g., in U.S. Pat.
No. 3,700,674 (i3ie:h1 et al.) and references cited therein, and U.S. Pat. No. 4,689,338 (Gerster). The others can be prepared as shown in step 2. Step 2 can be carried out by reacting a compound of Formula IV in an inert solvent (e.g., methylene chloride) with a chlorinating agent. (e. g., phosphorus oxychloride).
Preferred conditions involve chlorination in methylene chloride with a Vi.lsmeier reagent prepared from thionyl chloride a.nd N,N-dimethylformamide. In such a reaction, the compound of Formula IV is suspended in methylene chloride:, and a slight molar excess of thionyl chloride a.nd N,N-dimethylformamide is added to the suspension. Heating to reflux facilitates the chlorination.
Step 3 involves reacting a compound of Formula V in an inert solvent with an amine of the formula R1NH2 to provide a compound of Formula VI.
Some compounds of Formula VI are disclosed in U.S.
Pat. No. 4,689,338 (Gerster). The others can be prepared as shown in step 3. The reaction of step 3 is preferably carried out in the presence of a tertiary amine catalyst (such as triethylamine), and it is preferred to run the reaction without isolation of the chloro compound from step 2.
Step 4 involves: (i) reduction of the vitro group of the compound of Formula VI; (ii) reaction of the resulting 3-amino compound with a carboxylic acid or an equivalent thereof in order to provide a WO 92/06093 ~ ~~ ~ ~ ,~ .~ ~ -6- PCT/US91/06C~?
cyclized imidazo[4,5-c]quinoline; and (iii) oxidizing the quinoline nitrogen to provide the N-oxide of Formula II. Some compounds of Formula II are disclosed in U.S. Pat. No. 4,689,338 (Gerster). The others can be prepared as shown in step 4.
The reduction in step (4) is preferably carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon.
The reduction can be carried out conveniently on a Paar apparatus in an inert solvent such as toluene, ethyl acetate, or a lower alkanol. In part (ii) of step 4, a 3-amino compound is reacted with (a) a 1,1-dialkoxyalkyl alkanoate such as diethoxymethyl acetate, or (b) a carboxylic acid that will introduce the desired RZ group, or (c) a trialkyl ortho ester of the formula RZC(Oalkyl)3, wherein "alkyl" is an alkyl group containing 1 to about 4 carbon atoms, or (d) a combination of such a carboxylic acid with such a trialkyl ortho ester to provide an imidazo[4,5-c]quinoline. The reaction can be carried out by heating, e.g., at about 130°C, in the presence of an acid, preferably an alkanoic acid having one more carbon atom than R2.
Part (iii) of step (4) provides an intermediate of Formula II. The quinoline nitrogen is oxidized with a conventional oxidizing agent that is capable of forming N-oxides. Preferred oxidizing agents include peroxyacids (such as peroxyacetic acid) and hydrogen peroxide. Preferred conditions involve mild heating (e.g., at about 50°C-60°C) in an ethanolic solution of peroxyacetic acid.
A lIi-imidazo[4,5-c]quinolin-4-amine is prepared in step (5) of the Reaction Scheme. Step (5) involves (i) reacting a compound of Formula II with an acylating agent; (ii) reacting the product with an aminating agent; and (iii) isolating the compound of Formula I. Part (i) of step (5) involves reacting an N-oxide with an acylating agent. Suitable acylating agents include alkyl- or aryl- sulfonyl chlorides (e. g., benzenesulfonyl chloride, methanesulfonyl .CVO 92/06093 PCT/US91/06682 _7_ ~~~~~J~
chloride, p-toluenesulfonyl chloride). Arylsulfonyl chlorides are prei.erred. p-Toluenesulfonyl chloride is most preferred.. Part (ii) of step (5) involves reacting the product of part (i) with an excess of an aminating agent. Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.,g., ammonium carbonate, ammonium bicarbonate, and ammonium phosphate). Ammonium hydroxide is prefs:rred. The reaction of step (5) is preferably carried out by dissolving the N-oxide from Formula II in an ~~~nert solvent such as methylene chloride, adding t:he aminating agent to the solution, and then adding the acylating agent. Preferred conditions involvE~ cooling to about 0°C to about 5°C
during the addition of the acylating agent. Heating or cooling can be used to control the rate of the reaction. The product compound of Formula I can be isolated by the conventional means disclosed in U.S.
Pat. No. 4,689,338 (Gerster), such as, for example, removal of the solvent and recrystallization from an appropriate solvent (e.g., N,N-dimethylformamide) or solvent mixture, car by dissolution in an appropriate solvent (e.g., met:hanol) and re-precipitation by addition of a second solvent in which the compound is insoluble.
The compounds of Formula I can be used in the form of acid addition salts such as hydrochlorides, di.hydrogen sulfates, trihydrogen phosphates, hydrogren nitrates, methane sulfonates and salts of other pharmaceutically acceptable acids.
Pharmaceutically acceptable acid-addition salts of compounds of Formula I are generally prepared by reaction of the respective compound with an equimolar amount of a relatively strong acid, preferably an inorganic acid such as hydrochloric, sulfuric or phosphoric acid or an organic acid such as methanesulfonic acid in a polar solvent. Isolation of the salt is facilitated by the addition of a solvent in which the salt is insoluble (e. g., diethyl ether).
WO 92/06093 PCT/US91 /0668'.
The 1H-imidazo[4,5-c]quinolin-4-amines prepared by the process of this invention are disclosed in U.S. Pat. Nos. 4,689,338 (Gerster) and 4,929,624 (Gerster et al.) as antiviral agents. The process as described above is illustrated in the Example below for the synthesis of 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine.
The process affords the final product in a 40% overall yield from 4-hydroxyquinoline.
In the following Example, all reactions were run with stirring under an atmosphere of dry nitrogen unless otherwise indicated. The particular materials and amounts thereof recited in the Example, as well as other conditions and details, should not be construed to unduly limit the invention.
EXAMPLE
The preparation of 1-(2-methylpropyl)-iH-imidazo[4,5-c]quinolin-4-amine.
Part A
4-Hydroxyquinoline (26.2 g, 0.18 mol) was added to propionic acid (250 mL) and the solution was heated to about 125°C. Nitric acid (16.0 mL of a 70 percent aqueous solution, 0.36 mol) was added dropwise with stirring. When the addition was complete, the mixture was stirred at about 125°C for 10 minutes, then allowed to cool to room temperature. The mixture was diluted with ethanol. The precipitated solid was filtered, washed sequentially with ethanol, water, and ethanol, and dried to afford 3-nitro-4-hydroxyquinoline (27.7 g, 86%) as a light yellow powder.
Part B
The compound 3-nitro-4-hydroxyquinoline (19.0 g, 0.10 mol) was suspended in dichloromethane (200 mL). Thionyl chloride (8.1 mL, 0.11 mol) and N,N-dimethylformamide (8.5 mL, 0.11 mol) were added.
..~'O 92/06093 PCT/US91/06682 The reaction mixture was then heated for 3.5 hours at reflux, during which time a small amount of solid precipitated. The reaction mixture was then cooled to -15°C and a solution of isobutylamine (15.1 mL, 0.15 mol), and triethy:Lamine (20.9 mL, 0.15 mol) in dichloromethane (:L00 mL) was added in a slow stream with vigorous swirling. During the addition the temperature of thEa reaction mixture rose to 20°C. The resulting solution was heated at reflux for 30 minutes, cooled, and the solvent was removed at reduced pressures t:o afford a yellow solid product.
The product was s7Lurried in water, filtered, washed with water, and dried partially. The partially dried product was then .:lurried in ethanol (75 mL), filtered, washed successively with a small amount of ethanol and a sma7.1 amount of diethyl ether, and dried at reduced pressure to afford a yellow crystalline solid product. A second crop of product was obtained by evaporating the: ethanol filtrate. The total amount of N-(2-methylpropyl)-3-nitro-4-quinolinamine was 23.3 g.
Par C
N-(2-met:hylpropyl)-3-nitro-4-quinolinamine (61.3 g, 0.25 mol) was placed in a Paar apparatus along with 5% Pt/C (1.5 g), magnesium sulfate (60 g), ethyl acetate (750 mL), and formic acid (400 mL). The mixture was placed. under a hydrogen atmosphere (about 50 psi) and hydrogenated. The catalyst was removed by filtration and the solvent was evaporated to afford the crude product. The crude product was dissolved in 98% formic acid (400 mL) and refluxed for 1 hour. The resulting solution was evaporated to dryness and the resulting solid was dissolved in ethanol (400 mL).
Peroxyacetic acid (63 mL of an acetic acid solution containing 32% peroxyacetic acid based on the total weight of the solution, 0.3 mol) was added and the solution was heated at 56°C for about 0.5 hour. The solution was then cooled and the solvents were removed 4o at reduced pressure. The residue was then WO 92/06093 PCT/US91 /066F-'' .~0~~~.1~3~z _10_ co-evaporated with heptane (3x300 mL) to afford a solid. The solid was dissolved in dichloromethane (550 mL) in a Hirsch flask and ammonium hydroxide (125 mL of an aqueous solution containing 28% ammonia by weight based on the total weight of the solution) was added. The resulting mixture was cooled to 0°C and a solution of p-toluenesulfonyl chloride in dichloromethane (52.4 g, 0.275 mol, in 125 mL
dichloromethane) was added dropwise over 20 min. The temperature was maintained in the range of 0°C to about 5°C during the addition. After the addition, the reaction mixture was stirred at room temperature for 2 hours. The precipitate was filtered, slurried in ethanol, filtered again, and washed sequentially with ethanol and ether to afford solid 1-(2-methylpropyl)-iH-imidazo[4,5-c]quinolin-4-amine (45.6 g, 76% crude yield). A l0 g sample of the crude product was dissolved in concentrated hydrochloric acid (25 mL) and the solution was treated with sodium dithionite (3.3 g). The solution was then heated in a steam bath for 15 minutes and diluted with water (75 mL). The product precipitated and was filtered. The solid was then dissolved in a minimum amount of methanol and precipitated by addition of a solution of potassium hydroxide in methanol. The precipitate was filtered and washed with methanol to afford 6.6 g (50%
purified yield) of 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine with melting point and spectral properties identical to those of an authentic sample.
$i (R)n The Reaction Scheme begins with a 4-hydroxyquinoline of Formula III. Many 4-hydroxyquinolines of Formula III are commercially available. The others are known and/or can be prepared readily by those skilled in the art. Step 1 involves nitration of a 4-hydroxyquinoline to provide a 3-nitro-4-hydroxyquinoline of Formula IV. Conventional conditions for such reactions are well known.
Preferred conditions in the instance where n is zero, which afford a product of Formula IV in superior yield compared with conolitions used in the prior art, involve heating at: about 125°C-130°C in propionic acid in the presence of nitric acid. Preferred conditions in other instances. will depend upon the particular 4-hydroxyquinoline: used in step 1, and those skilled in the art will be: able to select suitable conditions.
In step 2, a 3-vitro-4-hydroxyquinoline is chlorinated at the: 4-position to provide a 3-vitro-4-chloroquinoline of Formula V. Some compounds of Formula V are knowm and disclosed, e.g., in U.S. Pat.
No. 3,700,674 (i3ie:h1 et al.) and references cited therein, and U.S. Pat. No. 4,689,338 (Gerster). The others can be prepared as shown in step 2. Step 2 can be carried out by reacting a compound of Formula IV in an inert solvent (e.g., methylene chloride) with a chlorinating agent. (e. g., phosphorus oxychloride).
Preferred conditions involve chlorination in methylene chloride with a Vi.lsmeier reagent prepared from thionyl chloride a.nd N,N-dimethylformamide. In such a reaction, the compound of Formula IV is suspended in methylene chloride:, and a slight molar excess of thionyl chloride a.nd N,N-dimethylformamide is added to the suspension. Heating to reflux facilitates the chlorination.
Step 3 involves reacting a compound of Formula V in an inert solvent with an amine of the formula R1NH2 to provide a compound of Formula VI.
Some compounds of Formula VI are disclosed in U.S.
Pat. No. 4,689,338 (Gerster). The others can be prepared as shown in step 3. The reaction of step 3 is preferably carried out in the presence of a tertiary amine catalyst (such as triethylamine), and it is preferred to run the reaction without isolation of the chloro compound from step 2.
Step 4 involves: (i) reduction of the vitro group of the compound of Formula VI; (ii) reaction of the resulting 3-amino compound with a carboxylic acid or an equivalent thereof in order to provide a WO 92/06093 ~ ~~ ~ ~ ,~ .~ ~ -6- PCT/US91/06C~?
cyclized imidazo[4,5-c]quinoline; and (iii) oxidizing the quinoline nitrogen to provide the N-oxide of Formula II. Some compounds of Formula II are disclosed in U.S. Pat. No. 4,689,338 (Gerster). The others can be prepared as shown in step 4.
The reduction in step (4) is preferably carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon.
The reduction can be carried out conveniently on a Paar apparatus in an inert solvent such as toluene, ethyl acetate, or a lower alkanol. In part (ii) of step 4, a 3-amino compound is reacted with (a) a 1,1-dialkoxyalkyl alkanoate such as diethoxymethyl acetate, or (b) a carboxylic acid that will introduce the desired RZ group, or (c) a trialkyl ortho ester of the formula RZC(Oalkyl)3, wherein "alkyl" is an alkyl group containing 1 to about 4 carbon atoms, or (d) a combination of such a carboxylic acid with such a trialkyl ortho ester to provide an imidazo[4,5-c]quinoline. The reaction can be carried out by heating, e.g., at about 130°C, in the presence of an acid, preferably an alkanoic acid having one more carbon atom than R2.
Part (iii) of step (4) provides an intermediate of Formula II. The quinoline nitrogen is oxidized with a conventional oxidizing agent that is capable of forming N-oxides. Preferred oxidizing agents include peroxyacids (such as peroxyacetic acid) and hydrogen peroxide. Preferred conditions involve mild heating (e.g., at about 50°C-60°C) in an ethanolic solution of peroxyacetic acid.
A lIi-imidazo[4,5-c]quinolin-4-amine is prepared in step (5) of the Reaction Scheme. Step (5) involves (i) reacting a compound of Formula II with an acylating agent; (ii) reacting the product with an aminating agent; and (iii) isolating the compound of Formula I. Part (i) of step (5) involves reacting an N-oxide with an acylating agent. Suitable acylating agents include alkyl- or aryl- sulfonyl chlorides (e. g., benzenesulfonyl chloride, methanesulfonyl .CVO 92/06093 PCT/US91/06682 _7_ ~~~~~J~
chloride, p-toluenesulfonyl chloride). Arylsulfonyl chlorides are prei.erred. p-Toluenesulfonyl chloride is most preferred.. Part (ii) of step (5) involves reacting the product of part (i) with an excess of an aminating agent. Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.,g., ammonium carbonate, ammonium bicarbonate, and ammonium phosphate). Ammonium hydroxide is prefs:rred. The reaction of step (5) is preferably carried out by dissolving the N-oxide from Formula II in an ~~~nert solvent such as methylene chloride, adding t:he aminating agent to the solution, and then adding the acylating agent. Preferred conditions involvE~ cooling to about 0°C to about 5°C
during the addition of the acylating agent. Heating or cooling can be used to control the rate of the reaction. The product compound of Formula I can be isolated by the conventional means disclosed in U.S.
Pat. No. 4,689,338 (Gerster), such as, for example, removal of the solvent and recrystallization from an appropriate solvent (e.g., N,N-dimethylformamide) or solvent mixture, car by dissolution in an appropriate solvent (e.g., met:hanol) and re-precipitation by addition of a second solvent in which the compound is insoluble.
The compounds of Formula I can be used in the form of acid addition salts such as hydrochlorides, di.hydrogen sulfates, trihydrogen phosphates, hydrogren nitrates, methane sulfonates and salts of other pharmaceutically acceptable acids.
Pharmaceutically acceptable acid-addition salts of compounds of Formula I are generally prepared by reaction of the respective compound with an equimolar amount of a relatively strong acid, preferably an inorganic acid such as hydrochloric, sulfuric or phosphoric acid or an organic acid such as methanesulfonic acid in a polar solvent. Isolation of the salt is facilitated by the addition of a solvent in which the salt is insoluble (e. g., diethyl ether).
WO 92/06093 PCT/US91 /0668'.
The 1H-imidazo[4,5-c]quinolin-4-amines prepared by the process of this invention are disclosed in U.S. Pat. Nos. 4,689,338 (Gerster) and 4,929,624 (Gerster et al.) as antiviral agents. The process as described above is illustrated in the Example below for the synthesis of 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine.
The process affords the final product in a 40% overall yield from 4-hydroxyquinoline.
In the following Example, all reactions were run with stirring under an atmosphere of dry nitrogen unless otherwise indicated. The particular materials and amounts thereof recited in the Example, as well as other conditions and details, should not be construed to unduly limit the invention.
EXAMPLE
The preparation of 1-(2-methylpropyl)-iH-imidazo[4,5-c]quinolin-4-amine.
Part A
4-Hydroxyquinoline (26.2 g, 0.18 mol) was added to propionic acid (250 mL) and the solution was heated to about 125°C. Nitric acid (16.0 mL of a 70 percent aqueous solution, 0.36 mol) was added dropwise with stirring. When the addition was complete, the mixture was stirred at about 125°C for 10 minutes, then allowed to cool to room temperature. The mixture was diluted with ethanol. The precipitated solid was filtered, washed sequentially with ethanol, water, and ethanol, and dried to afford 3-nitro-4-hydroxyquinoline (27.7 g, 86%) as a light yellow powder.
Part B
The compound 3-nitro-4-hydroxyquinoline (19.0 g, 0.10 mol) was suspended in dichloromethane (200 mL). Thionyl chloride (8.1 mL, 0.11 mol) and N,N-dimethylformamide (8.5 mL, 0.11 mol) were added.
..~'O 92/06093 PCT/US91/06682 The reaction mixture was then heated for 3.5 hours at reflux, during which time a small amount of solid precipitated. The reaction mixture was then cooled to -15°C and a solution of isobutylamine (15.1 mL, 0.15 mol), and triethy:Lamine (20.9 mL, 0.15 mol) in dichloromethane (:L00 mL) was added in a slow stream with vigorous swirling. During the addition the temperature of thEa reaction mixture rose to 20°C. The resulting solution was heated at reflux for 30 minutes, cooled, and the solvent was removed at reduced pressures t:o afford a yellow solid product.
The product was s7Lurried in water, filtered, washed with water, and dried partially. The partially dried product was then .:lurried in ethanol (75 mL), filtered, washed successively with a small amount of ethanol and a sma7.1 amount of diethyl ether, and dried at reduced pressure to afford a yellow crystalline solid product. A second crop of product was obtained by evaporating the: ethanol filtrate. The total amount of N-(2-methylpropyl)-3-nitro-4-quinolinamine was 23.3 g.
Par C
N-(2-met:hylpropyl)-3-nitro-4-quinolinamine (61.3 g, 0.25 mol) was placed in a Paar apparatus along with 5% Pt/C (1.5 g), magnesium sulfate (60 g), ethyl acetate (750 mL), and formic acid (400 mL). The mixture was placed. under a hydrogen atmosphere (about 50 psi) and hydrogenated. The catalyst was removed by filtration and the solvent was evaporated to afford the crude product. The crude product was dissolved in 98% formic acid (400 mL) and refluxed for 1 hour. The resulting solution was evaporated to dryness and the resulting solid was dissolved in ethanol (400 mL).
Peroxyacetic acid (63 mL of an acetic acid solution containing 32% peroxyacetic acid based on the total weight of the solution, 0.3 mol) was added and the solution was heated at 56°C for about 0.5 hour. The solution was then cooled and the solvents were removed 4o at reduced pressure. The residue was then WO 92/06093 PCT/US91 /066F-'' .~0~~~.1~3~z _10_ co-evaporated with heptane (3x300 mL) to afford a solid. The solid was dissolved in dichloromethane (550 mL) in a Hirsch flask and ammonium hydroxide (125 mL of an aqueous solution containing 28% ammonia by weight based on the total weight of the solution) was added. The resulting mixture was cooled to 0°C and a solution of p-toluenesulfonyl chloride in dichloromethane (52.4 g, 0.275 mol, in 125 mL
dichloromethane) was added dropwise over 20 min. The temperature was maintained in the range of 0°C to about 5°C during the addition. After the addition, the reaction mixture was stirred at room temperature for 2 hours. The precipitate was filtered, slurried in ethanol, filtered again, and washed sequentially with ethanol and ether to afford solid 1-(2-methylpropyl)-iH-imidazo[4,5-c]quinolin-4-amine (45.6 g, 76% crude yield). A l0 g sample of the crude product was dissolved in concentrated hydrochloric acid (25 mL) and the solution was treated with sodium dithionite (3.3 g). The solution was then heated in a steam bath for 15 minutes and diluted with water (75 mL). The product precipitated and was filtered. The solid was then dissolved in a minimum amount of methanol and precipitated by addition of a solution of potassium hydroxide in methanol. The precipitate was filtered and washed with methanol to afford 6.6 g (50%
purified yield) of 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine with melting point and spectral properties identical to those of an authentic sample.
Claims (6)
1 A process for preparing a compound of the formula:
wherein:
R1 is straight chain or branched chain alkyl of 1 to 10 carbon atoms; straight chain or branched chain alkenyl of 3 to 10 carbon atoms wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the 1-nitrogen; substituted straight chain or branched chain alkenyl of 3 to 10 carbon atoms wherein the olefinic unsaturation is at least one carbon atom removed from the 1-nitrogen, wherein the substituent is selected from the group consisting of lower alkyl, cycloalkyl of 3 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms substituted by lower alkyl; and substituted straight chain or branched chain alkyl of 1 to 10 carbon atoms, wherein the substituent is selected from the group con-sisting of lower alkyl, cycloalkyl of 3 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms substituted by lower alkyl;
R2 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing 1 to 8 carbon atoms; benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than 6 carbon atoms;
each R is independently selected from the group consisting of lower alkoxy, halogen, and lower alkyl, and n is an integer from zero to 2, with the proviso that if n is 2, then said R groups together contain no more than 6 carbon atoms; or a pharmaceutically acceptable acid addition salt thereof, which process comprises the steps of:~
(i) providing a compound of Formula II
wherein R, n, R1, and R2 are as defined above;
(ii) reacting the compound of Formula II
with an acylating agent; and (iii) reacting the product of step (ii) with an aminating agent in an inert solvent to provide a compound of Formula I; and (iv) isolating the compound of Formula I
or a pharmaceutically acceptable acid addition salt therof.
wherein:
R1 is straight chain or branched chain alkyl of 1 to 10 carbon atoms; straight chain or branched chain alkenyl of 3 to 10 carbon atoms wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the 1-nitrogen; substituted straight chain or branched chain alkenyl of 3 to 10 carbon atoms wherein the olefinic unsaturation is at least one carbon atom removed from the 1-nitrogen, wherein the substituent is selected from the group consisting of lower alkyl, cycloalkyl of 3 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms substituted by lower alkyl; and substituted straight chain or branched chain alkyl of 1 to 10 carbon atoms, wherein the substituent is selected from the group con-sisting of lower alkyl, cycloalkyl of 3 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms substituted by lower alkyl;
R2 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing 1 to 8 carbon atoms; benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than 6 carbon atoms;
each R is independently selected from the group consisting of lower alkoxy, halogen, and lower alkyl, and n is an integer from zero to 2, with the proviso that if n is 2, then said R groups together contain no more than 6 carbon atoms; or a pharmaceutically acceptable acid addition salt thereof, which process comprises the steps of:~
(i) providing a compound of Formula II
wherein R, n, R1, and R2 are as defined above;
(ii) reacting the compound of Formula II
with an acylating agent; and (iii) reacting the product of step (ii) with an aminating agent in an inert solvent to provide a compound of Formula I; and (iv) isolating the compound of Formula I
or a pharmaceutically acceptable acid addition salt therof.
2. A process according to Claim 1, wherein the acylating agent is an arylsulfonyl chloride.
3. A process according to Claim 1, wherein the acylating agent is p-toluenesulfonyl chloride.
4. A process according to Claim 1, wherein the aminating agent is ammonia or an ammonium salt.
5. A process according to Claim 1, wherein the aminating agent is ammonium hydroxide.
6. A process according to Claim 1 wherein the compound is 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59307890A | 1990-10-05 | 1990-10-05 | |
| US593,078 | 1990-10-05 | ||
| PCT/US1991/006682 WO1992006093A1 (en) | 1990-10-05 | 1991-09-13 | Process for the preparation of imidazo[4,5-c]quinolin-4-amines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2093132A1 CA2093132A1 (en) | 1992-04-06 |
| CA2093132C true CA2093132C (en) | 2002-02-26 |
Family
ID=24373289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002093132A Expired - Lifetime CA2093132C (en) | 1990-10-05 | 1991-09-13 | Process for the preparation of imidazo[4,5-c]quinolin-4-amines |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5367076A (en) |
| EP (1) | EP0553202B1 (en) |
| AT (1) | ATE121088T1 (en) |
| CA (1) | CA2093132C (en) |
| DE (1) | DE69108920T2 (en) |
| DK (1) | DK0553202T3 (en) |
| ES (1) | ES2071340T3 (en) |
| HU (1) | HU217080B (en) |
| IE (1) | IE70302B1 (en) |
| NZ (1) | NZ239873A (en) |
| WO (1) | WO1992006093A1 (en) |
Families Citing this family (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4988815A (en) * | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
| US5395937A (en) * | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| US5352784A (en) * | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| JPH09500128A (en) * | 1993-07-15 | 1997-01-07 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | Imidazo [4,5-c] pyridin-4-amine |
| US5741908A (en) * | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
| US5693811A (en) * | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
| UA67760C2 (en) * | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines |
| CA2361936C (en) | 1999-01-08 | 2009-06-16 | 3M Innovative Properties Company | Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
| US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
| US20020058674A1 (en) | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
| US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US6573273B1 (en) | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
| US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
| JP3436512B2 (en) * | 1999-12-28 | 2003-08-11 | 株式会社デンソー | Accelerator device |
| UA74852C2 (en) * | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
| US6660747B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6664264B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| US6677348B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| WO2006091720A2 (en) * | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
| US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| US7226928B2 (en) * | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
| JP2005501550A (en) * | 2001-08-30 | 2005-01-20 | スリーエム イノベイティブ プロパティズ カンパニー | Maturation of plasmacytoid dendritic cells using immune response modifier molecules |
| DE60230340D1 (en) * | 2001-11-16 | 2009-01-22 | 3M Innovative Properties Co | N-Ä4- (4-amino-2-ethyl-1H-imidazoÄ4,5-quinolin-1-yl) -butyl-methanesulfonamide, pharmaceutical composition containing the same and their use |
| NZ532769A (en) * | 2001-11-29 | 2005-12-23 | 3M Innovative Properties Co | Pharmaceutical formulations comprising an immune response modifier |
| CA2365732A1 (en) * | 2001-12-20 | 2003-06-20 | Ibm Canada Limited-Ibm Canada Limitee | Testing measurements |
| US6677349B1 (en) * | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| ES2541132T3 (en) * | 2002-02-22 | 2015-07-16 | Meda Ab | Method to reduce and treat UV-B-induced immunosuppression |
| WO2003101949A2 (en) | 2002-05-29 | 2003-12-11 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
| MXPA04012199A (en) * | 2002-06-07 | 2005-02-25 | 3M Innovative Properties Co | Ether substituted imidazopyridines. |
| CN1315828C (en) | 2002-07-23 | 2007-05-16 | 特瓦药厂私人有限公司 | Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates |
| JP2005537287A (en) | 2002-07-26 | 2005-12-08 | テバ ジョジセルジャール レースベニュタールシャシャーグ | 1H-imidazo [4,5-c] quinolin-4-amine with novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinoline-4-carboxamide intermediates Manufacturing |
| EP1545597B1 (en) | 2002-08-15 | 2010-11-17 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
| AU2003299082A1 (en) * | 2002-09-26 | 2004-04-19 | 3M Innovative Properties Company | 1h-imidazo dimers |
| AU2003287324A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
| WO2004053452A2 (en) * | 2002-12-11 | 2004-06-24 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
| WO2004058759A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| CA2511538C (en) * | 2002-12-30 | 2013-11-26 | 3M Innovative Properties Company | Immunostimulatory combinations |
| US7375180B2 (en) * | 2003-02-13 | 2008-05-20 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and Toll-like receptor 8 |
| EP1599726A4 (en) * | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | Selective modulation of tlr-mediated biological activity |
| CA2517528A1 (en) | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of uv-induced epidermal neoplasia |
| EP1605943A4 (en) * | 2003-03-07 | 2008-01-16 | 3M Innovative Properties Co | 1-amino 1h-imidazoquinolines |
| US7163947B2 (en) * | 2003-03-07 | 2007-01-16 | 3M Innovative Properties Company | 1-Amino 1H-imidazoquinolines |
| AU2004220465A1 (en) * | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
| US7699057B2 (en) * | 2003-03-13 | 2010-04-20 | 3M Innovative Properties Company | Methods for treating skin lesions |
| CA2518282C (en) * | 2003-03-13 | 2012-11-06 | 3M Innovative Properties Company | Methods of improving skin quality |
| US20040192585A1 (en) * | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
| US20040202720A1 (en) * | 2003-04-10 | 2004-10-14 | 3M Innovative Properties Company | Delivery of immune response modifier compounds using metal-containing particulate support materials |
| US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| WO2004110991A2 (en) * | 2003-06-06 | 2004-12-23 | 3M Innovative Properties Company | PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES |
| AR044466A1 (en) * | 2003-06-06 | 2005-09-14 | 3M Innovative Properties Co | PROCESS FOR THE PREPARATION OF IMIDAZO [4,5-C] PIRIDIN-4-AMINAS |
| CA2534042A1 (en) * | 2003-07-31 | 2005-02-10 | 3M Innovative Properties Company | Compositions for encapsulation and controlled release |
| CA2534313C (en) * | 2003-08-05 | 2013-03-19 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
| TW200510412A (en) * | 2003-08-12 | 2005-03-16 | 3M Innovative Properties Co | Oxime substituted imidazo-containing compounds |
| CA2535338C (en) * | 2003-08-14 | 2013-05-28 | 3M Innovative Properties Company | Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers |
| JP2007504145A (en) * | 2003-08-25 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Immunostimulatory combinations and treatments |
| US8961477B2 (en) | 2003-08-25 | 2015-02-24 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
| CA2536136C (en) | 2003-08-27 | 2012-10-30 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
| JP2007504172A (en) * | 2003-09-02 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Methods for treatment of mucosa related symptoms |
| JP2007504269A (en) | 2003-09-05 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Method for treating CD5 + B cell lymphoma |
| EP1664342A4 (en) * | 2003-09-17 | 2007-12-26 | 3M Innovative Properties Co | Selective modulation of tlr gene expression |
| WO2005033049A2 (en) * | 2003-10-01 | 2005-04-14 | Taro Pharmaceuticals U.S.A., Inc. | METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF |
| JP5043435B2 (en) | 2003-10-03 | 2012-10-10 | スリーエム イノベイティブ プロパティズ カンパニー | Alkoxy substituted imidazoquinolines |
| US7544697B2 (en) * | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| NZ546274A (en) | 2003-10-03 | 2009-12-24 | 3M Innovative Properties Co | Pyrazolopyridines and analags thereof |
| AU2004285575A1 (en) * | 2003-10-31 | 2005-05-12 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
| CN1906193A (en) * | 2003-11-14 | 2007-01-31 | 3M创新有限公司 | Oxime substituted imidazo ring compounds |
| AU2004291122A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
| AR046781A1 (en) | 2003-11-25 | 2005-12-21 | 3M Innovative Properties Co | IMIDAZOQUINOLINE DERIVATIVES. PHARMACEUTICAL COMPOSITIONS. |
| EP1686992A4 (en) * | 2003-11-25 | 2009-11-04 | 3M Innovative Properties Co | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| EP1689361A4 (en) * | 2003-12-02 | 2009-06-17 | 3M Innovative Properties Co | Therapeutic combinations and methods including irm compounds |
| US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| WO2005076783A2 (en) * | 2003-12-04 | 2005-08-25 | 3M Innovative Properties Company | Sulfone substituted imidazo ring ethers |
| WO2005066170A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
| CA2552101A1 (en) * | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds |
| US20050239735A1 (en) * | 2003-12-30 | 2005-10-27 | 3M Innovative Properties Company | Enhancement of immune responses |
| WO2005066169A2 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
| US20050201959A1 (en) * | 2004-03-11 | 2005-09-15 | Vvii Newco 2003, Inc. | Methods and compositions for altering skin coloration |
| AU2005222995B2 (en) * | 2004-03-15 | 2010-08-26 | 3M Innovative Properties Company | Immune response modifier formulations and methods |
| WO2005094531A2 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| EP1735010A4 (en) * | 2004-04-09 | 2008-08-27 | 3M Innovative Properties Co | Methods, compositions, and preparations for delivery of immune response modifiers |
| JP2008505857A (en) * | 2004-04-28 | 2008-02-28 | スリーエム イノベイティブ プロパティズ カンパニー | Compositions and methods for mucosal vaccination |
| US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
| US20080015184A1 (en) * | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
| US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| US7897609B2 (en) | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
| EP1765348B1 (en) * | 2004-06-18 | 2016-08-03 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| WO2006009826A1 (en) | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
| US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
| US8541438B2 (en) | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| US20060045886A1 (en) * | 2004-08-27 | 2006-03-02 | Kedl Ross M | HIV immunostimulatory compositions |
| AU2005282523A1 (en) | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1H imidazo ring systems and methods |
| AU2005282726B2 (en) * | 2004-09-02 | 2011-06-02 | 3M Innovative Properties Company | 1-alkoxy 1H-imidazo ring systems and methods |
| US20080193468A1 (en) * | 2004-09-08 | 2008-08-14 | Children's Medical Center Corporation | Method for Stimulating the Immune Response of Newborns |
| JP2008515928A (en) * | 2004-10-08 | 2008-05-15 | スリーエム イノベイティブ プロパティズ カンパニー | Adjuvants for DNA vaccines |
| US8034938B2 (en) | 2004-12-30 | 2011-10-11 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
| JP2008526765A (en) * | 2004-12-30 | 2008-07-24 | スリーエム イノベイティブ プロパティズ カンパニー | Treatment of skin metastases |
| US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
| CA2592897A1 (en) * | 2004-12-30 | 2006-07-13 | Takeda Pharmaceutical Company Limited | 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate |
| WO2006074003A2 (en) | 2004-12-30 | 2006-07-13 | 3M Innovative Properties Company | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS |
| WO2006084251A2 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
| AU2006212765B2 (en) | 2005-02-09 | 2012-02-02 | 3M Innovative Properties Company | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
| AU2006338521A1 (en) | 2005-02-09 | 2007-10-11 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods |
| CA2597446A1 (en) | 2005-02-11 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines and imidazonaphthyridines |
| JP2008530113A (en) | 2005-02-11 | 2008-08-07 | コーリー ファーマシューティカル グループ，インコーポレイテッド | Oxime and hydroxyramine substituted imidazo [4,5-c] ring compounds and methods |
| AU2006216799A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazonaphthyridines |
| JP2008531567A (en) | 2005-02-23 | 2008-08-14 | コーリー ファーマシューティカル グループ，インコーポレイテッド | Hydroxyalkyl-substituted imidazoquinoline compounds and methods |
| US8178677B2 (en) | 2005-02-23 | 2012-05-15 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinolines |
| AU2006216686A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Method of preferentially inducing the biosynthesis of interferon |
| MX2007011112A (en) * | 2005-03-14 | 2007-11-07 | Graceway Pharmaceuticals Llc | Method of treating actinic keratosis. |
| US7705269B2 (en) * | 2005-03-15 | 2010-04-27 | Lincoln Global, Inc. | Method and apparatus for advance warning and controlled shutdown in an arc processing system |
| US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
| US7943636B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| ITMI20051292A1 (en) * | 2005-07-08 | 2007-01-09 | Dipharma Spa | PROCEDURE FOR PURIFICATION OF IMIQUIMOD |
| EP1931352B1 (en) | 2005-08-22 | 2016-04-13 | The Regents of The University of California | Tlr agonists |
| EA200800782A1 (en) | 2005-09-09 | 2008-08-29 | Коли Фармасьютикал Груп, Инк. | AMIDA AND CARBAMATE DERIVATIVES N- {2- [4-AMINO-2- (ETOXIMETHYL) -1H-IMIDAZOLO [4,5-c] QUINOLIN-1-IL] -1,1-DIMETHYLETHYL} METHANE SULFONAMIDE AND METHODS |
| ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| US20070081962A1 (en) * | 2005-10-06 | 2007-04-12 | Amit Munshi | Novel delivery of immune response modifiers for removal of chronic tattoos |
| US20070100146A1 (en) * | 2005-11-03 | 2007-05-03 | Trevor Dzwiniel | Process for the preparation of imidazo[4,5-c]-quinolin-4-amines |
| JP5247458B2 (en) | 2005-11-04 | 2013-07-24 | スリーエム・イノベイティブ・プロパティーズ・カンパニー | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods |
| US7323568B2 (en) * | 2005-12-12 | 2008-01-29 | Chemagis Ltd. | Process for preparing Imiquimod |
| WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
| US8088788B2 (en) | 2006-03-15 | 2012-01-03 | 3M Innovative Properties Company | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods |
| WO2007106854A2 (en) | 2006-03-15 | 2007-09-20 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods |
| CA2653941C (en) | 2006-05-31 | 2013-01-08 | The Regents Of The University Of California | Substituted amino purine derivatives and uses thereof |
| US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
| US8178539B2 (en) | 2006-09-06 | 2012-05-15 | 3M Innovative Properties Company | Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods |
| US20080103310A1 (en) * | 2006-10-16 | 2008-05-01 | Janos Hajko | Preparation of 1H-imidazo[4,5-c]quinolin-4-amines via 1H-imidazo[4, 5-c]quinolin-4-phtalimide intermediates |
| US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
| US7943771B2 (en) * | 2007-01-24 | 2011-05-17 | Chemagis Ltd. | Imiquimod production process |
| PL2125007T3 (en) | 2007-02-07 | 2014-07-31 | Univ California | Conjugates of synthetic tlr agonists and uses therefor |
| US7659398B2 (en) * | 2007-02-14 | 2010-02-09 | Chemagis Ltd. | Imiquimod production process |
| WO2009099650A2 (en) * | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
| WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| MX2011008500A (en) | 2009-02-11 | 2011-09-26 | Univ California | Toll-like receptor modulators and treatment of diseases. |
| US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
| HUE033901T2 (en) | 2010-08-17 | 2018-01-29 | 3M Innovative Properties Co | Lipidated immune response modifier compound compositions, formulations, and methods |
| BR112013031039B1 (en) | 2011-06-03 | 2020-04-28 | 3M Innovative Properties Co | hydrazine compounds 1h-imidazoquinoline-4-amines, conjugates made from these compounds, composition and pharmaceutical composition comprising said compounds and conjugates, uses thereof and method of manufacturing the conjugate |
| JP6460789B2 (en) | 2011-06-03 | 2019-01-30 | スリーエム イノベイティブ プロパティズ カンパニー | Heterobifunctional linker having polyethylene glycol segment and immune response modulating complex prepared from the linker |
| US20130023736A1 (en) | 2011-07-21 | 2013-01-24 | Stanley Dale Harpstead | Systems for drug delivery and monitoring |
| DK2844282T3 (en) | 2012-05-04 | 2019-07-15 | Pfizer | PROSTATA ASSOCIATED ANTIGENES AND VACCINE-BASED IMMUNTERAPIREGIMENES |
| ES2538880B1 (en) * | 2013-12-24 | 2016-09-08 | Laboratorios Viñas S.A. | A procedure to obtain 4-amino-1-isobutyl-1H-imidazo [4,5-c] quinolein |
| CN104402878A (en) * | 2014-10-22 | 2015-03-11 | 天方药业有限公司 | Preparation method of imiquimod |
| US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
| EP3728255B1 (en) | 2017-12-20 | 2022-01-26 | 3M Innovative Properties Company | Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US4929624A (en) * | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| US4988815A (en) * | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
-
1991
- 1991-09-13 ES ES91918854T patent/ES2071340T3/en not_active Expired - Lifetime
- 1991-09-13 DK DK91918854.0T patent/DK0553202T3/en active
- 1991-09-13 EP EP91918854A patent/EP0553202B1/en not_active Expired - Lifetime
- 1991-09-13 WO PCT/US1991/006682 patent/WO1992006093A1/en active IP Right Grant
- 1991-09-13 HU HU9300965A patent/HU217080B/en unknown
- 1991-09-13 DE DE69108920T patent/DE69108920T2/en not_active Expired - Lifetime
- 1991-09-13 AT AT91918854T patent/ATE121088T1/en not_active IP Right Cessation
- 1991-09-13 CA CA002093132A patent/CA2093132C/en not_active Expired - Lifetime
- 1991-09-20 IE IE330791A patent/IE70302B1/en not_active IP Right Cessation
- 1991-09-20 NZ NZ239873A patent/NZ239873A/en not_active IP Right Cessation
-
1992
- 1992-04-30 US US07/879,149 patent/US5367076A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0553202A1 (en) | 1993-08-04 |
| EP0553202B1 (en) | 1995-04-12 |
| ATE121088T1 (en) | 1995-04-15 |
| IE70302B1 (en) | 1996-11-13 |
| DE69108920D1 (en) | 1995-05-18 |
| WO1992006093A1 (en) | 1992-04-16 |
| HUT63416A (en) | 1993-08-30 |
| HU217080B (en) | 1999-11-29 |
| CA2093132A1 (en) | 1992-04-06 |
| NZ239873A (en) | 1993-12-23 |
| DK0553202T3 (en) | 1995-07-03 |
| US5367076A (en) | 1994-11-22 |
| DE69108920T2 (en) | 1995-11-30 |
| IE913307A1 (en) | 1992-04-08 |
| HU9300965D0 (en) | 1993-06-28 |
| ES2071340T3 (en) | 1995-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2093132C (en) | Process for the preparation of imidazo[4,5-c]quinolin-4-amines | |
| CA2104781C (en) | Process for imidazo[4,5-c]quinolin-4-amines | |
| AU717564B2 (en) | Process for preparing tetrahydroimidazoquinolinamines | |
| AU721036B2 (en) | Process for preparing imidazoquinolinamines | |
| JP6061158B2 (en) | Synthesis intermediate of 6- (7-((1-aminocyclopropyl) methoxy) -6-methoxyquinolin-4-yloxy) -N-methyl-1-naphthamide, or a pharmaceutically acceptable salt thereof, and its use | |
| SU1333234A3 (en) | Method of producing the derivatives of n-phenylbenzamide or salts thereof | |
| HU223947B1 (en) | 1-substituted 1h-imidazo [4,5-c]quinolin-4-amines, intermediate and pharmaceutical compositions | |
| HUT73671A (en) | Process for preparing quinoline amines | |
| EP0376166A1 (en) | Condensed quinoline system compound and process of preparation thereof | |
| JP4208463B2 (en) | Intermediates for the production of quinolonecarboxylic acid derivatives | |
| JP4208464B2 (en) | Method for producing naphthyridine-3-carboxylic acid derivative | |
| CZ110398A3 (en) | Process for preparing antimalarial substances | |
| JPH07121931B2 (en) | Benzo [b] furan derivative | |
| Belov et al. | Quinone Imines with a Fused Azine Ring: III. Synthesis and Reactivity of 8-p-Tolylsulfonylimino-5, 8-dihydroquinolin-5-one Derivatives | |
| JPH05301874A (en) | 3-nitrosonaphthylidine derivative and its production | |
| JPH0539270A (en) | Production of 8-chloroquinolone derivative | |
| HU220667B1 (en) | Quinolin derivatives for producing 1- and 2-substituted 1h-imidazo[4,5-c]quinolin-4-amines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |